[바이오코리아2026] 안종성 코오롱바이오텍 전무 "연매출 4조 기대"

The potential commercialization of TG-C in the US market signifies a major shift for Kolon Biotech from a group-dependent manufacturing unit to a global CGT CDMO powerhouse. This transition highlights the growing scale of cell and gene therapy production capabilities and the strategic importance of building large-scale manufacturing track records within the biotech industry.